- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02628509
Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedure (WiTAVi)
Onset and Offset of Von Willebrand Factor Multimemirization Defects in Cardiovascular Disease: the Case of the Molecular Sensor of Blood Flow
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was designed to understand the Von Willebrand Factor (VWF) abnormalities observed in association with implantation of different devices in cardiovascular diseases (percutaneous valve replacement and circulatory support devices).
The main objective of the study was to describe the time-course of VWF abnormalities onset/offset during implantation of devices in cardiovascular diseases.
Adult patients > 18 years who need a CF-LVAD or trans-aortic valve implantation are included in this cohort; Blood samples are obtained just before procedures
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Sophie Susen, MD, PhD
- Phone Number: 33320445937
- Email: sophie.susen@chru-lille.fr
Study Locations
-
-
-
Lille, France, 59037
- Recruiting
- Lille University Hospital
-
Contact:
- Sophie Susen, MD,PhD
- Phone Number: 33320445937
- Email: sophie.susen@chru-lille.fr
-
Principal Investigator:
- Eric van Belle, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients > 18 years who need a mechanical circulatory support due to advanced heart failure or undergoing trans-aortic-valve-replacement to treat aortic stenosis.
- Informed consent of the patient or support person in case of disability at baseline (patient intubated and ventilated)
Exclusion Criteria:
- Patient with a known severe bleeding disorder
- Patient refusal or environment
- Minor patients
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
cardiac devices
patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
|
patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Von Willebrand factor (VWF) multimer defects
Time Frame: 180 minutes after device implantation
|
VWF multimeric analysis is performed by electrophoresis.
The results of HMW-multimers are expressed as the relative amount of the largest multimers (mer>15) of the sample compared with those of the normal pooled plasma (NPP standard human plasma Siemens healthcare diagnostics, Marburg, Germany, coefficient of variation=11%) present on each gel.
4-6 With this method the HMW-multimer ratio is defined as the HMW-multimers (>15-mer) in patient plasma sample divided by HMW-multimers in normal pool plasma, the HMW-multimer ratio of normal pooled plasma is 1 (by definition) and an HMW-multimer defect is defined as a reduced HMW-multimer-ratio (<1).
|
180 minutes after device implantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
platelet function analyser- ADP (PFA-ADP) closure time
Time Frame: 5, 15,30, 60 minutes; day 1 , day 7 after device implantation
|
The PFA test is initially performed with the Collagen/Epinepherine membrane.
A normal Col/ADP closure time (<180 seconds) excludes the presence of a significant platelet function defect.
|
5, 15,30, 60 minutes; day 1 , day 7 after device implantation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sophie Susen, MD, PhD, Lille University Hospital
Publications and helpful links
General Publications
- Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, Staels B, Goudemand J, Jude B, Lenting PJ, Susen S. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res. 2015 Mar 27;116(7):1193-201. doi: 10.1161/CIRCRESAHA.116.305046. Epub 2015 Feb 10.
- Vincent F, Spillemaeker H, Kyheng M, Belin-Vincent C, Delhaye C, Pierache A, Denimal T, Verdier B, Debry N, Moussa M, Schurtz G, Porouchani S, Cosenza A, Juthier F, Pamart T, Richardson M, Coisne A, Hertault A, Sobocinski J, Modine T, Pontana F, Duhamel A, Labreuche J, Van Belle E. Ultrasound Guidance to Reduce Vascular and Bleeding Complications of Percutaneous Transfemoral Transcatheter Aortic Valve Replacement: A Propensity Score-Matched Comparison. J Am Heart Assoc. 2020 Mar 17;9(6):e014916. doi: 10.1161/JAHA.119.014916. Epub 2020 Mar 16.
- Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, Jeanpierre E, Levade M, Hurt C, Rousse N, Dally JB, Debry N, Dallongeville J, Vincentelli A, Delhaye C, Auffray JL, Juthier F, Schurtz G, Lemesle G, Caspar T, Morel O, Dumonteil N, Duhamel A, Paris C, Dupont-Prado A, Legendre P, Mouquet F, Marchant B, Hermoire S, Corseaux D, Moussa K, Manchuelle A, Bauchart JJ, Loobuyck V, Caron C, Zawadzki C, Leroy F, Bodart JC, Staels B, Goudemand J, Lenting PJ, Susen S. Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. N Engl J Med. 2016 Jul 28;375(4):335-44. doi: 10.1056/NEJMoa1505643.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NI_59
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
Clinical Trials on cardiac devices
-
University Hospital, Basel, SwitzerlandCompletedAtrial Fibrillation (AF)Switzerland
-
Dacima ConsultingTunisian Society of Cardiology and Cardiovascular SurgeryCompletedCardiac Implantable Electronic DevicesTunisia
-
Medtronic Cardiac Rhythm and Heart FailureRecruitingArrhythmias, Cardiac | Bradycardia | TachycardiaUnited States
-
Klinik für Kardiologie, Pneumologie und AngiologieRecruitingBradycardia | Syncope | Ventricular Fibrillation | Ventricular Tachycardia | Tachycardia | Sudden Cardiac DeathGermany
-
Abbott Medical DevicesCompletedBradycardia | TachycardiaAustralia, India
-
Lawson Health Research InstituteCompleted
-
Boston Scientific CorporationCompletedHeart FailureUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting
-
Medtronic ItaliaMedtronicWithdrawnArrhythmias, Cardiac | Bradycardia | SyncopeSaudi Arabia, Italy, Japan, United Kingdom, Germany, Iceland, India, South Africa, Sweden
-
Peking University Third HospitalPeking UniversityRecruitingHeart Failure | Percutaneous Coronary Intervention | Cardiometabolic Syndrome | Structural Heart AbnormalityChina